Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02904096 · ClinicalTrials.gov registry record · NA
Radiesse® Safety Study For the Treatment of Hands
A NA study of Volume Loss in the Dorsum of the Hand, sponsored by Merz North America.
- Completed
- Registry status
- NA
- Development phase
- 256
- Enrollment target
- 9
- Study locations
NCT02904096: Completed NA study of Volume Loss in the Dorsum of the Hand, sponsored by Merz North America.
NCT02904096 is a NA study of Volume Loss in the Dorsum of the Hand that has completed, run by Merz North America. The registered enrollment target is 256 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). The trial reports 9 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02904096, a NA study of Volume Loss in the Dorsum of the Hand, has completed, sponsored by Merz North America.
- COMPLETED
- Registry status
- NA
- Development phase
- 256 participants
- Enrollment target
- 9
- Study locations
Study Summary
The primary objective of this study is to evaluate the safety of Radiesse implantation for very severe volume loss in the dorsum of the hand at 6 months after treatment.
Primary Outcome
Proportion refers to percentage of subjects with device-and/or injection-related severe TEAEs.
Conditions Studied
Interventions
- DEVICE Radiesse injectable implant and 2% lidocaine HCL
Study Locations (9)
California
- Merz Investigative Site #0010393 - Sacramento
- Merz Investigative Site #0010321 - San Diego
- Merz Investigative Site #0010358 - Vista
- Merz Investigative Site #0010099 - West Hollywood
New York
- Merz Investigative Site #0010405 - New York
- Merz Investigative Site #0010406 - New York
Texas
- Merz Investigative Site #0010322 - Austin
- Merz Investigative Site #0010125 - Plano
Washington
- Merz Investigative Site #0010392 - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2016-06-10 |
| Est. Completion | 2019-01-09 |
| Phase | NA |
What the finished NCT02904096 record still lists
NCT02904096 is an interventional study that assigns participants to a tested intervention. The registered 256 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Volume Loss in the Dorsum of the Hand appearing as the primary indexed condition, and to 1 intervention - of which Radiesse injectable implant and 2% lidocaine HCL is the first listed.
NCT02904096 lists 9 locations in 4 states (California, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT02904096 about?
NCT02904096 is a clinical study titled "Radiesse® Safety Study For the Treatment of Hands". The primary objective of this study is to evaluate the safety of Radiesse implantation for very severe volume loss in the dorsum of the hand at 6 months after treatment.
What is the current status of trial NCT02904096?
This trial is currently completed. It is a NA study. The enrollment target is 256 participants. The study started on 2016-06-10. Estimated completion is 2019-01-09.
What conditions does trial NCT02904096 study?
This clinical trial studies the following conditions: Volume Loss in the Dorsum of the Hand.
What interventions are being tested in trial NCT02904096?
The interventions under investigation include: Radiesse injectable implant and 2% lidocaine HCL (DEVICE).
Who is sponsoring clinical trial NCT02904096?
This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02904096 being conducted?
This trial has 9 study locations across California, New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Volume Loss in the Dorsum of the Hand
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02904096's enrollment target sits among peer trials
256 404th of 2000 higher than 1,594 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02464696 · 256 participants · NA
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
- NCT03793062 · 256 participants
Genetic and Epigenetic Basis of Chronic Wounds
- NCT04322318 · 256 participants · Phase 2
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- NCT04468360 · 256 participants · Phase 2
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI